Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab in 6–11-year-old children with type 2 (eosinophilic) asthma
CTR20263164Phase 3Active
- Sponsor
- GSK
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of depemokimab in asthma, sponsored by GSK. Started Aug 2026; status: active.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20263164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263164.